Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
Aim. To estimate ibrutinib efficacy in the treatment of first early CLL relapses and in patients with ≥ 2 lines of preceding therapy. Analysis of treatment results in patients with del(17p) and monitoring of minimal residual disease (MRD) and ibrutinib safety profile. Materials & Methods. The...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2018-01-01
|
| Series: | Kliničeskaâ onkogematologiâ |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/wp-content/uploads/2018/01/5-1.pdf |